Skip to content
Sucroferric oxyhydroxide
Velphoro (sucroferric oxyhydroxide) is an unknown pharmaceutical. Sucroferric oxyhydroxide was first approved as Velphoro on 2014-08-26. It is used to treat hyperphosphatemia in the USA. It has been approved in Europe to treat hyperphosphatemia and renal dialysis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
therapeuticsD013812
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
velphoro New Drug Application2020-11-06
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hyperphosphatemiaHP_0002905D054559—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemia
— V03AE05: Sucroferric oxyhydroxide
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperphosphatemiaD054559HP_0002905——1124
HypoalbuminemiaD034141HP_0003073———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSUCROFERRIC OXYHYDROXIDE
INN—
Description
Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD). It is used in form of chewable tablets.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID12134-57-5
RxCUI—
ChEMBL IDCHEMBL3039566
ChEBI ID—
PubChem CID—
DrugBankDB09146
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 229 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
712 adverse events reported
View more details